165 related articles for article (PubMed ID: 35835312)
1. Predictive factors of the contracture test for diagnosing malignant hyperthermia in a Brazilian population sample: a retrospective observational study.
de Mello JM; Andrade PV; Santos JM; Oliveira ASB; Vainzof M; do Amaral JLG; Almeida da Silva HC
Braz J Anesthesiol; 2023; 73(2):145-152. PubMed ID: 35835312
[TBL] [Abstract][Full Text] [Related]
2. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group.
Ording H; Brancadoro V; Cozzolino S; Ellis FR; Glauber V; Gonano EF; Halsall PJ; Hartung E; Heffron JJ; Heytens L; Kozak-Ribbens G; Kress H; Krivosic-Horber R; Lehmann-Horn F; Mortier W; Nivoche Y; Ranklev-Twetman E; Sigurdsson S; Snoeck M; Stieglitz P; Tegazzin V; Urwyler A; Wappler F
Acta Anaesthesiol Scand; 1997 Sep; 41(8):955-66. PubMed ID: 9311391
[TBL] [Abstract][Full Text] [Related]
3. Results of contracture tests with halothane, caffeine, and ryanodine depend on different malignant hyperthermia-associated ryanodine receptor gene mutations.
Fiege M; Wappler F; Weisshorn R; Ulrich Gerbershagen M; Steinfath M; Schulte Am Esch J
Anesthesiology; 2002 Aug; 97(2):345-50. PubMed ID: 12151923
[TBL] [Abstract][Full Text] [Related]
4. An analysis of the predictive probability of the in vitro contracture test for determining susceptibility to malignant hyperthermia.
Hopkins PM; Ellis FR; Halsall PJ; Stewart AD
Anesth Analg; 1997 Mar; 84(3):648-56. PubMed ID: 9052318
[TBL] [Abstract][Full Text] [Related]
5. [Diagnosis of malignant hyperthermia susceptibility. 1. The significance of in vitro susceptibility tests].
Mortier W; Breucking E
Anaesthesist; 1993 Oct; 42(10):675-83. PubMed ID: 8250201
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the segregation of the RYR1 C1840T mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family.
Serfas KD; Bose D; Patel L; Wrogemann K; Phillips MS; MacLennan DH; Greenberg CR
Anesthesiology; 1996 Feb; 84(2):322-9. PubMed ID: 8602662
[TBL] [Abstract][Full Text] [Related]
7. Is there a link between exertional heat stroke and susceptibility to malignant hyperthermia?
Sagui E; Montigon C; Abriat A; Jouvion A; Duron-Martinaud S; Canini F; Zagnoli F; Bendahan D; Figarella-Branger D; Brégigeon M; Brosset C
PLoS One; 2015; 10(8):e0135496. PubMed ID: 26258863
[TBL] [Abstract][Full Text] [Related]
8. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes.
Robinson RL; Brooks C; Brown SL; Ellis FR; Halsall PJ; Quinnell RJ; Shaw MA; Hopkins PM
Hum Mutat; 2002 Aug; 20(2):88-97. PubMed ID: 12124989
[TBL] [Abstract][Full Text] [Related]
9. Effect of cocaine on the contracture response to 1% halothane in patients undergoing diagnostic muscle biopsy for malignant hyperthermia.
Sato N; Brum JM; Mitsumoto H; DeBoer GE
Can J Anaesth; 1995 Feb; 42(2):158-62. PubMed ID: 7720160
[TBL] [Abstract][Full Text] [Related]
10. Multicentre evaluation of in vitro contracture testing with bolus administration of 4-chloro-m-cresol for diagnosis of malignant hyperthermia susceptibility.
Wappler F; Anetseder M; Baur CP; Censier K; Doetsch S; Felleiter P; Fiege M; Fricker R; Halsall PJ; Hartung E; Heffron JJ; Heytens L; Hopkins PM; Klingler W; Lehmann-Horn F; Nivoche Y; Tegazzin V; Tzanova I; Urwyler A; Weisshorn R; Schulte am Esch J
Eur J Anaesthesiol; 2003 Jul; 20(7):528-36. PubMed ID: 12884985
[TBL] [Abstract][Full Text] [Related]
11. [Profile of malignant hyperthermia susceptibility reports confirmed with muscular contracture test in Brazil].
Almeida da Silva HC; Ferreira G; Rodrigues G; Santos JMD; Andrade PV; Hortense A; Vaz Perez M; Amaral JLGD
Braz J Anesthesiol; 2019; 69(2):152-159. PubMed ID: 30935497
[TBL] [Abstract][Full Text] [Related]
12. The ryanodine contracture test may help diagnose susceptibility to malignant hyperthermia.
Reuter DA; Anetseder M; Müller R; Roewer N; Hartung EJ
Can J Anaesth; 2003; 50(7):643-8. PubMed ID: 12944436
[TBL] [Abstract][Full Text] [Related]
13. C1840-T mutation in the human skeletal muscle ryanodine receptor gene: frequency in northern German families susceptible to malignant hyperthermia and the relationship to in vitro contracture response.
Steinfath M; Singh S; Scholz J; Becker K; Lenzen C; Wappler F; Köchling A; Roewer N; Schulte am Esch J
J Mol Med (Berl); 1995 Jan; 73(1):35-40. PubMed ID: 7633940
[TBL] [Abstract][Full Text] [Related]
14. Mutation screening in the ryanodine receptor 1 gene (RYR1) in patients susceptible to malignant hyperthermia who show definite IVCT results: identification of three novel mutations.
Rueffert H; Olthoff D; Deutrich C; Meinecke CD; Froster UG
Acta Anaesthesiol Scand; 2002 Jul; 46(6):692-8. PubMed ID: 12059893
[TBL] [Abstract][Full Text] [Related]
15. Malignant hyperthermia (MH) diagnostics: a comparison between the halothane-caffeine- and the ryanodine-contracture-test results in MH susceptible, normal and control muscle.
Hartung E; Koob M; Anetseder M; Schoemig P; Krauspe R; Hogrefe G; Engelhardt W
Acta Anaesthesiol Scand; 1996 Apr; 40(4):437-44. PubMed ID: 8738688
[TBL] [Abstract][Full Text] [Related]
16. Genetic effects on the variability of the halothane and caffeine muscle contracture tests.
Urwyler A; Censier K; Kaufmann MA; Drewe J
Anesthesiology; 1994 Jun; 80(6):1287-95. PubMed ID: 8010475
[TBL] [Abstract][Full Text] [Related]
17. A blinded comparison of noninvasive, in vivo phosphorus nuclear magnetic resonance spectroscopy and the in vitro halothane/caffeine contracture test in the evaluation of malignant hyperthermia susceptibility.
Olgin J; Rosenberg H; Allen G; Seestedt R; Chance B
Anesth Analg; 1991 Jan; 72(1):36-47. PubMed ID: 1984374
[TBL] [Abstract][Full Text] [Related]
18. Use of the caffeine-halothane contracture test for the diagnosis of malignant hyperthermia in Brazil.
Sudo RT; Cunha LB; Carmo PL; Matos AR; Trachez MM; Cardoso LA; Aguiar MI; Abreu AV; Zapata-Sudo G
Braz J Med Biol Res; 2010 Jun; 43(6):549-56. PubMed ID: 20464345
[TBL] [Abstract][Full Text] [Related]
19. The Israeli Diagnostic Center for Malignant Hyperthermia: 7-years' accumulated experience.
Glauber V; Ben Abraham R; Zweig A; Perel A
Isr J Med Sci; 1997 Oct; 33(10):643-7. PubMed ID: 9397136
[TBL] [Abstract][Full Text] [Related]
20. Determination of a positive malignant hyperthermia (MH) disposition without the in vitro contracture test in families carrying the RYR1 Arg614Cys mutation.
Rueffert H; Olthoff D; Deutrich C; Froster UG
Clin Genet; 2001 Aug; 60(2):117-24. PubMed ID: 11553045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
